Trial Profile
A retrospective analysis of EWOG-MDS group to evaluate the efficacy and safety of low-dose Azacitidine in children and young adults with Myelodysplastic syndrome
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Sep 2016
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 29 Sep 2016 New trial record